Core Viewpoint - The company received approval from the National Medical Products Administration for clinical trials of HS387 tablets, a selective KIF18A inhibitor aimed at treating advanced solid tumors such as high-grade serous ovarian cancer and non-small cell lung cancer [1] Company Summary - The company has invested approximately 42.41 million RMB in the research and development of HS387 tablets [1]

Core Viewpoint - The credit rating of Shenzhen Micron Biotech Co., Ltd. remains stable at A+, reflecting strong innovation capabilities and good sales liquidity, despite facing challenges such as increased debt pressure and competition risks in the market [3][6][10]. Company Overview - Shenzhen Micron Biotech Co., Ltd. has a strong product pipeline, with core products receiving new indications and recommendations in updated treatment guidelines [3][4]. - The company’s main financial data shows total assets of 33.12 billion, total debt of 14.10 billion, and a net profit loss of 0.19 billion for 2025 [3][4]. Financial Performance - The company’s operating income for 2024 is projected at 6.58 billion, a slight increase from 5.24 billion in 2023, but net profit is expected to remain negative [3][4]. - The sales revenue from the core product, Sidabamine, accounts for 75.92% of total sales, indicating a high dependency on a single product [4][12]. Market Position and Competition - The company faces competition from newly approved drugs such as Golisib, which poses a direct threat to Sidabamine in the treatment of peripheral T-cell lymphoma (PTCL) [5][12]. - The market for diabetes medications is highly competitive, with the company’s product, Seglitazone, having a low market share of less than 1% as of 2024 [20]. Research and Development - The company has halted the submission of a new indication for the drug Xioroni due to clinical trial results, leading to a full impairment of related development expenses [4][5]. - Ongoing clinical trials for Sidabamine and Seglitazone are crucial for future growth, with significant investments made in these areas [17][20]. Industry Environment - The pharmaceutical manufacturing industry is expected to stabilize, with a growing demand for medications, particularly in chronic disease and cancer treatment [10][11]. - Price reductions in drug pricing due to policy changes continue to pressure the industry, but the long-term outlook remains positive as companies adapt to new market conditions [10][11].

Industry Overview - Synthetic biology has gained significant attention from both the scientific and investment communities, with increasing research and application prospects across various fields [1][2] - The global synthetic biology market was approximately $12.2 billion in 2022, showing a year-on-year growth of 28.42%, and is projected to reach $15.1 billion in 2023 and $19 billion in 2024, with a forecast of $24.3 billion by 2025 [1] - Major countries, including the US, UK, EU, and China, are intensifying their strategic investments and policy support in synthetic biology, positioning it as a strategic high ground in future global competition [1][3] Company Developments - Haizheng Pharmaceutical has established a joint venture, Lian Sheng Synthetic, with a registered capital of 350 million yuan, aiming to enter the synthetic biology sector [2] - Shenghe Biotechnology has launched China's first production line for natural product biosynthesis, which will serve various industries including cosmetics and pharmaceuticals [2] - Lian Sheng Synthetic is set to invest 170 million yuan in a flexible production line for synthetic biology, with its first product expected to be launched in August [5] Market Dynamics - The economic value of synthetic biology and bio-manufacturing is projected to reach $100 billion by 2025, with an expectation that 60% of material production will be achieved through bio-manufacturing methods [5] - The industry is characterized by a competitive landscape where companies are striving to convert midstream technologies into marketable products, emphasizing the importance of industrialization capabilities [5][9] Challenges and Opportunities - The transition from laboratory to commercial application in synthetic biology faces multiple challenges, including technical feasibility, engineering conversion, and market adaptability [7][8] - The industry is experiencing a "valley of death" in industrialization, where many promising technologies fail to scale up due to the lack of pilot testing [8] - Despite the challenges, the integration of AI and machine learning is expected to enhance research capabilities and support the development of synthetic biology [6] Strategic Insights - The current landscape indicates a need for innovation to avoid price competition and to develop high-value products that can lead the market [9] - The establishment of supportive policies at the provincial and national levels in China is anticipated to further guide and promote the healthy development of the synthetic biology industry [6]

Investment Rating - The report maintains a "Recommended" rating for the new materials industry [1]. Core Insights - The new materials sector is positioned as a crucial direction for the chemical industry, currently experiencing rapid growth in downstream demand. With policy support and technological breakthroughs, domestic new materials are expected to accelerate their long-term growth. The report emphasizes that "one generation of materials leads to one generation of industries," highlighting the foundational role of the new materials industry in supporting other sectors [4][14]. Summary by Sections 1. Electronic Information Sector - Focus on semiconductor materials, display materials, and 5G materials. Recent developments include Meta Platforms planning to launch a next-generation AI ASIC chip by Q4 2025, and Huawei applying for a quad-chiplet packaging design patent for its next AI chip [5][21][22]. 2. Aerospace Sector - Key areas of interest include PI films, precision ceramics, and carbon fibers. The report notes the participation of China's new generation stealth fighters at the Paris Air Show, showcasing advancements in military aviation technology [7][8]. 3. New Energy Sector - Emphasis on photovoltaic materials, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials. The report anticipates a significant breakthrough in China's new energy revolution by 2030, driven by hydrogen energy development [9][10]. 4. Biotechnology Sector - Focus on synthetic biology and scientific services. The establishment of a new synthetic biology company by Haizheng Pharmaceutical marks a strategic move into the high-end synthetic biology industry [11][12]. 5. Energy Conservation and Environmental Protection Sector - Attention on adsorbent resins, membrane materials, and biodegradable plastics. The report highlights the development of hazardous waste disposal facilities in Zhejiang Province, indicating a comprehensive approach to waste management [13][14]. 6. Industry Rating and Investment Strategy - The new materials sector is expected to benefit from downstream application sectors, entering a favorable economic cycle. The report maintains a "Recommended" rating for the new materials industry [14].

【SynBioCon】 获 悉， 6月19日电， 海正药业 公告称其拟与全资子公司瀚晖制药之香港全资子公司 辉正国际合资 设立 合成生物 学独立子公司 ，注册资本 3.5亿元 。新公 司名为 浙江沄生合成生物科 技有限公司 （简称 沄生合成 ）。 海正药业 拟认缴出资2.6亿元，占74.29%，辉正国际拟认缴出资0.9亿元，占注册资本的25.71%。公 告显示，该合资公司将整合资源，结合辉正国际在香港的平台优势，为公司 合成生物 学业务的专业 化、规模化发展提供有力支撑。 资本事件 | 海正药业 海正药业成立于1956年，2000年海正在上海证券交易所上市。公司目前市值超百亿，是国内重要的原 料药生产企业，其产品涵盖多个治疗领域，包括抗肿瘤、心血管系统、抗感染等。 2024年前三季度，公司营收为78.75亿元，归母净利润为5.15亿元。随着肖卫红出任公司董事长，公 司将合成生物视为除人用药、动物药之外的新兴业务。 携手浙工大，加快合成生物项目落地 自2024年11月， 海正药业携手 浙江工业大学 共建 合成生物制造创新研究院 ，双方合作有望加速合 成生物学技术从前端研发到产业化落地的进程。 未来公司将基于合成 ...

Group 1 - The market experienced fluctuations with mixed performance among the three major indices, while the Hang Seng-Hushen Hong Kong Innovative Drug Selected 50 Index fell by 0.39% [1] - Notable gainers among the constituent stocks included Nuotai Bio, which rose over 5%, along with other companies such as CanSino, China National Pharmaceutical Group, and Shanghai Pharmaceuticals [1] - The Tianhong Innovative Drug ETF (517380) has seen a continuous decline for five consecutive days, dropping by 0.47% in the morning session [1] Group 2 - The Tianhong Innovative Drug ETF (517380) is the largest ETF in the market that spans across the Shanghai, Shenzhen, and Hong Kong markets, and is the only ETF tracking the Hang Seng-Hushen Hong Kong Innovative Drug Selected 50 Index [2] - As of the first quarter of 2025, the ETF achieved a net value growth rate of 24.96% over the past year, outperforming its benchmark by 5.45% [2] - The American Diabetes Association (ADA) conference, recognized as the largest diabetes conference globally, is set to take place from June 20-23, showcasing over 200 specialized reports, particularly focusing on GLP-1 class drugs [2] Group 3 - The ADA conference is considered a significant platform for Chinese innovative drug companies to showcase their research capabilities in the GLP-1 field, potentially boosting the related industry chain [3] - The innovative drug sector has garnered high market attention due to various factors including policy support, international expansion, and performance, despite some individual stock performance divergence [3] - The innovative drug sector remains a crucial investment theme in the industry, as highlighted by the ongoing developments and market interest [3]

Group 1 - Fujian Quanzhou has launched an instant settlement model for basic medical insurance funds to improve settlement efficiency and alleviate financial pressure on designated medical institutions [1] - The instant settlement reform establishes an efficient mechanism of "daily payment + monthly settlement" by compressing the settlement cycle and increasing payment frequency [1] Group 2 - Shanghai Pharmaceuticals announced that its subsidiary in Thailand received approval from the Thai FDA for the registration of Pregabalin capsules, which are used to treat various types of neuropathic pain and as an adjunct therapy for epilepsy [3] - Gilead Sciences announced that the FDA approved its injectable HIV-1 capsid inhibitor Yeztugo for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection in adults and adolescents weighing 35 kg or more [4] Group 3 - Haizheng Pharmaceutical plans to establish a joint venture for synthetic biology with its wholly-owned subsidiary, with a registered capital of 350 million yuan, aiming to support the professional and large-scale development of its synthetic biology business [6] - Nuo Vision announced a plan to repurchase shares worth between 5 million and 10 million yuan for employee stock ownership plans, with a repurchase price not exceeding 30 yuan per share [7] - Tiankang Biological's subsidiary Tiankang Pharmaceutical has completed the counseling acceptance for its public stock issuance and listing on the Beijing Stock Exchange [8] Group 4 - Baike Biological received approval from the National Medical Products Administration for clinical trials of its influenza virus split vaccine, which aims to provide new vaccination options for individuals aged 60 and above [10] - Dizhi Pharmaceutical announced the completion of patient enrollment for its global Phase III clinical study of its lung cancer targeted drug, which compares its drug with platinum-based chemotherapy for advanced non-small cell lung cancer [11] Group 5 - The FDA announced the launch of the "Commissioners National Priority Voucher" program to expedite new drug review times from approximately 10-12 months to 1-2 months for eligible companies [12] - Shengnuo Biological expects a net profit increase of 254% to 332% year-on-year for the first half of 2025, driven by strong performance in its peptide raw material business [12]

内容概要：台州市是浙江省下辖的地级市，位于浙江省中部沿海。近年来，台州市围绕打造"5+5+6"台 州特色现代化产业体系，一手抓传统产业、优势产业的巩固和优化，瞄准链主型企业、专精特新"小巨 人"企业等开展靶向招引，提升平台首位产业辨识度；一手抓新兴产业、未来产业的培育和壮大，聚焦 算力、氢能、低空经济、合成生物、机器人、泛半导体等六大未来产业，加快发展新质生产 力。"5+5+6"产业发展不断实现新突破，竞争力持续增强，产业生态日益完善，现代产业基础不断夯 实，助力经济稳步增长。 上市企业：水晶光电（002273）、航天彩虹（002389）、海正药业（600267）、海翔药业（002099）、 九洲药业（603456）、杰克股份（603337）、信质集团（002664）、百达精工（603331）、海正生材 （688203）、夜光明（873527）、华海药业（600521）、浙江永强（002489）、伟星股份（002003）、 伟星新材（002372）、永太科技（002326）、万盛股份（603010）、奥翔药业（603229）、本立科技 （301065）、联盛化学（301212）、浙江正特（001238）、天山 ...

Group 1 - The Ministry of Commerce will accelerate the review of export license applications related to rare earths, emphasizing the importance of maintaining global supply chain stability [1] - The Chinese photovoltaic industry is expected to see a significant reduction in production in Q3, with operating rates projected to decrease by 10%-15% compared to the previous quarter [2] - A video conference was held by three departments to strengthen safety management in the new energy vehicle sector, emphasizing the responsibility of manufacturers for product quality and safety [3] Group 2 - Yushu Technology has completed its C-round financing, led by major investors including China Mobile, Tencent, Alibaba, Ant Group, and Geely [4] - Beijing's government has introduced measures to support the gaming and esports industry, offering rewards up to 30 million yuan for companies enhancing R&D efficiency through AI and other technologies [5] - The gaming industry is receiving significant policy support from Beijing, with various financial incentives for hosting major esports events [7] Group 3 - The stock market indices have all declined, with the Shanghai Composite Index showing an increased possibility of forming a double top pattern [6] - Companies such as Giant Network and Changchun Technology are highlighted as potential beneficiaries of the favorable policies in the gaming sector [8] - Several companies have announced significant business developments, including H-share issuance plans and acquisitions in the semiconductor field [9]

Industry News - The Ministry of Industry and Information Technology and other departments held a video conference on enhancing the safety management of new energy vehicles, emphasizing the importance of long-termism and avoiding "involution" competition [8] - The Beijing Municipal Committee of the Communist Party of China issued support measures for the high-quality development of the gaming and esports industry, offering rewards up to 30 million yuan for projects that enhance R&D efficiency through computing power, model deployment, and data governance [8] - The National Narcotics Control Office announced the inclusion of 12 new psychoactive substances, including N-ethylhexedrone, into regulatory control to strengthen monitoring and prevent abuse [8] - The photovoltaic industry is expected to see a significant reduction in production in the third quarter, with operating rates projected to decrease by 10%-15% compared to the previous quarter, and low-price sales will undergo auditing [9] - The semiconductor sector is anticipated to experience a comprehensive recovery by 2025, with global semiconductor sales showing year-on-year and month-on-month growth in April [30] Company News - Taiji Co., Ltd. announced a change in its actual controller to the Hubei State-owned Assets Supervision and Administration Commission, leading to the resumption of its stock trading [12] - Lianchuang Optoelectronics reported strong demand for drone countermeasure equipment in the Middle East and is actively engaging with potential local customers and partners [13] - Shengnuo Bio announced an expected net profit increase of 254%-332% year-on-year for the first half of the year [15] - Yuncong Technology stated that its multi-modal AI technology for live detection and dynamic verification can be applied to stablecoin wallet scenarios [16] - Zhongyan Chemical announced plans to agree to a capital reduction by shareholders of Zhongyan Alkali Industry, which is expected to constitute a major asset restructuring [17]